Canaccord Genuity Maintains Hold on Immunocore Hldgs, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan maintains a Hold rating on Immunocore Holdings (IMCR) and raises the price target from $60 to $63.
February 29, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Hold rating on Immunocore Holdings and raises the price target from $60 to $63.
The increase in price target by Canaccord Genuity suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100